Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment

Hirofumi Ohashi, Koichi Watashi, Wakana Saso, +27

iScience

A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2

Kwang Su Kim, Keisuke Ejima, Shoya Iwanami, +11

PLoS Biology

Multidrug treatment with nelfinavir and cepharanthine against COVID-19

Hirofumi Ohashi, Koichi Watashi, Wakana Saso, +24

ImmunologyImmunotherapeuticsAntiviral DrugMultidrug TreatmentCovid-19 +15

Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey

Makoto Yoshida, Yurie Kobashi, Takeshi Kawamura, +17

Vaccines

ImmunodeficienciesCovid-19 EpidemiologyVaccine HesitancyFlu VaccinationCovid-19 +17

Estimation of the incubation period of COVID-19 using viral load data

Keisuke Ejima, Kwang Su Kim, Christina Ludema, +9

Epidemics

Viral Load DataIncubation PeriodViral LoadVirus EpidemiologyInfectious Disease Modelling +10

Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study

Shoya Iwanami, Keisuke Ejima, Kwang Su Kim, +17

PLoS Medicine

Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro

Kaho Shionoya, Masako Yamasaki, Shoya Iwanami, +14

Frontiers in Microbiology

Modelling SARS-CoV-2 Dynamics: Implications for Therapy

Kwang Su Kim, Keisuke Ejima, Yusuke Ito, +8

Virus EpidemiologySars-cov-2 DynamicsViral DiagnosticsScientific CommunityCovid-19 Pandemic +11

Revisiting the guidelines for ending isolation for COVID-19 patients

Yong Dam Jeong, Keisuke Ejima, Kwang Su Kim, +10

eLife

VaccinationInfectious Disease ModellingPersonalized ApproachCovid-19 PandemicPersonalized Strategy +10

Designing isolation guidelines for COVID-19 patients with rapid antigen tests

Yong Dam Jeong, Keisuke Ejima, Kwang Su Kim, +9

Nature Communications